RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Inclusion Body Myositis: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
The NORAD-Pumilio regulatory axis in the evolution of inclusion body myositis.
Tong Lingying et al., Journal of neuropathology and experimental neurology (1 October 2026)
https://pubmed.ncbi.nlm.nih.gov/41991167/
- 2.
Paradigm shift in the pathomechanisms and treatment of inclusion body myositis: at the crossroads of cell-autonomous muscle degeneration and immune activation.
Suzuki Naoki et al., Current opinion in neurology (1 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42615630/
- 3.
3.38eP Clinical characteristics, healthcare utilization, and unmet needs of patients with inclusion body myositis: a nationwide questionnaire survey
Satoshi Yamashita et al., Neuromuscular Disorders (29 September 2026)
https://doi.org/10.1016/j.nmd.2026.107051
- 4.
3.40eP No association between inclusion body myositis and cancer risk in a population-based case-control study
Pierre Larsson et al., Neuromuscular Disorders (29 September 2026)
https://doi.org/10.1016/j.nmd.2026.107053
- 5.
3.43eP Divergent functional trajectories in inclusion body myositis: sirolimus, methotrexate, and untreated patients across two countries
Bruna Moreira de Souza Proença et al., Neuromuscular Disorders (29 September 2026)
https://doi.org/10.1016/j.nmd.2026.107056
Clinical Trials : Australian Sites
Ask your doctor whether you or your child may be eligible for any of these trials. Each has its ID and full eligibility criteria at the link shown.
- 1.
Long-term Extension Study of Ulviprubart (ABC008) in Subjects With Inclusion Body Myositis
NCT06450886 · Active (not recruiting) · Phase 2 / Phase 3 · Abcuro, Inc.
Ages 40 and over
https://clinicaltrials.gov/study/NCT06450886
- 2.
A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis
NCT05721573 · Completed · Phase 2 / Phase 3 · Abcuro, Inc.
Ages 40 and over
https://clinicaltrials.gov/study/NCT05721573
- 3.
Phase III Trial of Sirolimus in IBM
NCT04789070 · Active (not recruiting) · Phase 3 · University of Kansas Medical Center
Ages 45 and over
https://clinicaltrials.gov/study/NCT04789070
- 4.
A Phase 1 Study of ABC008 in Ascending (Single Ascending Dose/Multiple Ascending Dose) Study in Patients With (IBM)
NCT04659031 · Completed · Phase 1 · Abcuro, Inc.
Ages 40 and over
https://clinicaltrials.gov/study/NCT04659031
- 5.
An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203
NCT02573467 · Completed · Phase 3 · Novartis Pharmaceuticals
Ages 36 and over
https://clinicaltrials.gov/study/NCT02573467
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Inclusion Body Myositis
Inclusion body myositis is a rare muscle disease that mostly starts after the age of 50. It causes slowly worsening weakness, often first in the thigh muscles and fingers, and can lead to falls and difficulty swallowing. No treatment has yet been proven to stop it, so care focuses on exercise, physiotherapy and managing symptoms while clinical trials continue.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
Sporadic inclusion body myopathy (sIBM) is the most common progressive degenerative skeletal muscle disease of older people with poorly understood pathogenesis. We assessed the involvement and impact of the noncoding RNA activated by DNA damage (NORAD) and its binding partner Pumilio (PUM) proteins on the evolution of the disease process in muscle biopsies from sIBM patients with mild or severe histopathologic changes. A disease severity-dependent increase in NORAD and PUM2 expression was present along with subsarcolemmal formations of NORAD-PUM (NP) bodies in the sIBM muscles. Similarly, Norad, Pum1, and Pum2 expression levels were upregulated as disease severity increased with age in VCP-A232E mice, a model for hereditary IBM. Crossbreeding VCP-A232E mice with Norad-/- mice leading to generation of VCP mutants with either single copy or the absence of Norad showed that Norad suppresses disease progression in the VCP-A232E model in a dose-dependent manner. Norad expression in the muscle from Pum2 overexpressing mice revealed significantly increased Norad transcripts in response to high Pum2 expression and the presence of NP bodies coalescing around muscle nuclei. Collectively, these findings provide strong evidence that elevated NORAD expression is a protective, compensatory response to disease-related induction of PUM2 activity in muscle.
Common Questions
What is Inclusion Body Myositis?
Inclusion body myositis is a rare muscle disease that mostly starts after the age of 50. It causes slowly worsening weakness, often first in the thigh muscles and fingers, and can lead to falls and difficulty swallowing. No treatment has yet been proven to stop it, so care focuses on exercise, physiotherapy and managing symptoms while clinical trials continue.
How many clinical trials are available for Inclusion Body Myositis?
RareWays currently indexes 30 clinical trials for Inclusion Body Myositis, of which 3 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Inclusion Body Myositis come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Inclusion Body Myositis.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.